Trial Profile
A Phase I Study of the Intrathecal Administration of Resiniferatoxin for Treating Severe Refractory Pain Associated With Advanced Cancer
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 27 Feb 2024
Price :
$35
*
At a glance
- Drugs Resiniferatoxin (Primary)
- Indications Cancer pain
- Focus Adverse reactions; First in man; Therapeutic Use
- 22 Feb 2024 Planned End Date changed from 7 Feb 2024 to 7 Feb 2025.
- 22 Feb 2024 Planned primary completion date changed from 7 Feb 2024 to 7 Feb 2025.
- 13 Sep 2023 Planned End Date changed from 31 Aug 2023 to 7 Feb 2024.